Aanlysis of prescriptions in multiple databases showing higher risk of COVID-19 hospitalization with acetaminophen use for COPD patients. Acetaminophen use was more prevalent in hospitalized patients compared to diagnosed patients (data from tables 1, 5, and S3).
Acetaminophen is also known as paracetamol, Tylenol, Panadol, Calpol, Tempra, Calprofen, Doliprane, Efferalgan, Grippostad C, Dolo, Acamol, Fevadol, Crocin, and Perfalgan.
|
risk of hospitalization, 29.3% higher, RR 1.29, p < 0.001, treatment 10,367, control 89,523, meta analysis of all databases combined.
|
|
risk of hospitalization, 51.7% higher, RR 1.52, p < 0.001, treatment 103 of 178 (57.9%), control 196 of 514 (38.1%), US CU-AMC.
|
|
risk of hospitalization, 5.1% higher, RR 1.05, p = 0.57, treatment 87 of 144 (60.4%), control 360 of 626 (57.5%), US CUIMC.
|
|
risk of hospitalization, 21.8% lower, RR 0.78, p = 0.02, treatment 64 of 319 (20.1%), control 1,585 of 6,181 (25.6%), NNT 18, US HealthVerity.
|
|
risk of hospitalization, 16.5% higher, RR 1.16, p < 0.001, treatment 2,597 of 4,983 (52.1%), control 28,320 of 63,279 (44.8%), US IQVIA OpenClaims.
|
|
risk of hospitalization, 57.0% higher, RR 1.57, p < 0.001, treatment 1,090 of 1,868 (58.4%), control 3,414 of 9,188 (37.2%), US Optum EHR.
|
|
risk of hospitalization, 47.2% higher, RR 1.47, p < 0.001, treatment 1,397 of 2,875 (48.6%), control 3,214 of 9,735 (33.0%), US VA-OMOP.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Moreno-Martos et al., 24 Jan 2022, retrospective, multiple countries, peer-reviewed, 24 authors, study period January 2020 - June 2020.
Contact:
d.r.z.morales@dundee.ac.uk.
Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe
David Moreno-Martos, Katia Verhamme, Anna Ostropolets, Kristin Kostka, Talita Duarte-Sales, Daniel Prieto-Alhambra, Thamir M Alshammari, Heba Alghoul, Waheed-Ul-Rahman Ahmed, Clair Blacketer, Scott Duvall, Lana Lai, Michael Matheny, Frederik Nyberg, Jose Posada, Peter Rijnbeek, Matthew Spotnitz, Anthony Sena, Nigam Shah, Marc Suchard, Seng Chan You, George Hripcak, Patrick Ryan, Daniel Morales
Wellcome Open Research, doi:10.12688/wellcomeopenres.17403.1
Background: Characterization studies of COVID-19 patients with Open Peer Review Approval Status
Data availability Underlying data Raw data from each database cannot be shared due to data privacy and governance requirements but raw data could be accessed according to the terms and conditions of each data source. The data source information including the terms and conditions for data access can be found in Table 8 . Analyses were performed locally in compliance with all applicable data privacy laws. All aggregate data has been made freely available for public inquiry (https://data.ohdsi.org/Covid19Charac-terizationCharybdis/). All analytic code and result sets have been made available (https://github.com/ohdsi-studies/Covid19Characterization-Charybdis). Archived analysis code as at time of publication: https://doi. org/10.5281/zenodo.5779264 28
David Moreno Martos We sincerely thank Dr. Tomlinson for reviewing the manuscript. 1. I think the definition of hospital cases will include those who caught COVID-19 while in hospital. These people tended to have a different disease course and may not represent the patients who were admitted with COVID-19. This could be pointed out as a limitation.
RESPONSE: The hospitalized cohort were defined as patients with a hospitalization episode and a clinical diagnosis of COVID- 2. There is likely to be some misclassification of asthmatics who were classified through medication use and were asthma had not been coded. These people may have fewer comorbidities than those with COPD: again this is simply a minor limitation.
..
References
Alqahtani, Oyelade, Aldhahir, Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis, PLoS One,
doi:10.1371/journal.pone.0233147Aveyard, Gao, Lindson, Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study, Lancet Respir Med,
doi:10.1016/S2213-2600(21)00095-3Burn, You, Sena, Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study, Nat Commun,
doi:10.1038/s41467-020-18849-zDu, Liang, Yang, Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study, Lancet Infect Dis,
doi:10.1016/S1473-3099(20)30243-7Duarte-Salles, Vizcaya, Pistillo, Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France,
doi:10.1101/2020.10.29.20222083Halpin, Criner, Papi, Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease, Am J Respir Crit Care Med,
doi:10.1164/rccm.202009-3533SOHripcsak, Duke, Shah, Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers, Stud Health Technol Inform
Ko, Chan, Chan, Molecular detection of respiratory pathogens and typing of human rhinovirus of adults hospitalized for exacerbation of asthma and chronic obstructive pulmonary disease, Respir Res,
doi:10.1186/s12931-019-1181-0Kohler, Kostka, Makadia, Using Real World Data to Understand HIV and COVID-19 in the U.S.A. and Spain: Characterizing Co-Infected Patients Across the Care Cascade, medRxiv,
doi:10.1101/2020.11.10.20229401Leung, Niikura, Yang, COVID-19 and COPD, Eur Respir J
Lund, Kristensen, Reilev, Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study, PLoS Med,
doi:10.1371/journal.pmed.1003308Morales, Ostropolets, Lai, Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe, J Asthma,
doi:10.1080/02770903.2021.2025392Moreno-Martos, Morales, Characteristics and outcomes of COVID-19 patients with COPD from the United States, South Korea, and Europe -Supplementary Materials, Zenodo
Prieto-Alhambra, Kostka, Duarte-Salles, Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS, Res Sq,
doi:10.21203/rs.3.rs-279400/v1Ramakrishnan, Nicolau, Jr, Langford, Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial, Lancet Respir Med,
doi:10.1016/S2213-2600(21)00160-0Richardson, Hirsch, Narasimhan, Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, JAMA,
doi:10.1001/jama.2020.6775Rimmer, Covid-19: Two thirds of healthcare workers who have died were from ethnic minorities, BMJ,
doi:10.1136/bmj.m1621Schultze, Walker, Mackenna, Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform, Lancet Respir Med,
doi:10.1016/S2213-2600(20)30415-XSena, Kostka, Schuemie, ohdsi-studies/ Covid19CharacterizationCharybdis: Charybdis v1
Voss, Makadia, Matcho, Feasibility and utility of applications of the common data model to multiple, disparate observational health databases, J Am Med Inform Assoc,
doi:10.1093/jamia/ocu023Wark, Tooze, Powell, Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission, Respirology,
doi:10.1111/resp.12099Wong, Mackenna, Morton, Use of non-steroidal antiinflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-219517Yang, Yu, Xu, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med,
doi:10.1016/S2213-2600(20)30079-5
